Also, STAT6D419 mutations are enriched in R/R DLBCL samples, as per a recent report, which implied the involvement of JAK/STAT signaling in therapeutic resistance [287]. This evidence concerns the gene SOAT1 and diffuse large B-cell lymphoma.